Antitumor effect of 3-[3-(2-chloroethyl)-3-nitrosoureido]-3-deoxy-D-glucopyranose on murine tumors.
The antitumor activity of a new derivative of nitrosourea, 3-[3-(2-chloroethyl)-3-nitrosoureido]-3-deoxy-D-glucopyranose (CNUG), against murine tumors was studied. CNUG showed remarkable antitumor activity against leukemias L1210 and P388, Lewis lung carcinoma, and sarcoma-180 (solid form). In particular, the majority of mice with leukemia or sarcoma-180 tumor were cured when they were given a single injection of CNUG on day 1 after tumor inoculation, and this treatment was more effective than daily treatment. CNUG was also active against sarcoma-180 grown in the brain, lung, liver or under the capsule of the kidney, and even against autochthonous lung tumor induced by 1-ethyl-1-nitrosourea. The number of peripheral leucocytes was depressed by the treatment with CNUG but this depression was less than that with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012673:Semustine / Q000627:therapeutic use; D013311:Streptozocin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D012673:Semustine; C007028:chlorozotocin; D013311:Streptozocin